Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
EOLS
EOLS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EOLS News
Evolus Sees Growing Demand for Beauty Products
5d ago
NASDAQ.COM
Evolus Achieves Profitability, Shares Surge 35%
5d ago
Fool
Evolus Shares Surge 36% After Exceeding Q4 2025 Earnings Expectations
6d ago
seekingalpha
Evolus Q4 2025 Earnings Call Insights
6d ago
seekingalpha
Evolus Releases 2026 Financial Outlook with Mixed Q4 Results
Mar 03 2026
seekingalpha
Evolus to Announce Q4 Earnings on March 3rd with Mixed Estimates
Mar 02 2026
seekingalpha
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
Jan 22 2026
Benzinga
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
Jan 09 2026
Newsfilter
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
Dec 28 2025
Yahoo Finance
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
Nov 06 2025
NASDAQ.COM
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Sep 22 2025
PRnewswire
Evolus Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Sep 12 2025
Newsfilter
BTIG Affirms Buy Rating for Evolus, Keeps $18 Price Target Intact
Sep 08 2025
Benzinga
Evolus Appoints Tatjana Mitchell as Chief Financial Officer
Sep 08 2025
Newsfilter
The Middle-Class Experience Has Transitioned from Stability to Strain
Aug 31 2025
WSJ
Evolus Shares Encouraging Results from Key Study on Evolysse Sculpt for Restoring Mid-Facial Volume
Aug 25 2025
NASDAQ.COM
Show More News
